News | News By Subject | News by Disease News By Date | Search News

Lymphoma, Hodgkin's News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
Why Investors Should Pay Attention to Seattle Genetics (SGEN)' Drug Trial     7/22/2016
FDA Designates Merck & Co. (MRK)'s Keytruda a Breakthrough for Classical Hodgkin Lymphoma     4/18/2016
Seattle Genetics (SGEN) to Hire 100 Employees in Anticipation of Company Growth     4/28/2015
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Bristol-Myers Squibb Company (BMY), Merck & Co. (MRK) Drugs Effective In Hodgkin Lymphoma Trials     12/9/2014
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Solid Lymphoma Data Points To Larger Potential For Epizyme (EPZM), Says Citi     11/21/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Bristol-Myers Squibb Company (BMY), Merck & Co. (MRK) Competing Hodgkin’s Drugs Look Comparable, Says Analyst     11/7/2014
Seattle Genetics, Inc. (SGEN) Gets Conditional OK for ADCETRIS® in EU; Triggers $25 Million Milestone Payment From Millennium: The Takeda Oncology Company     10/31/2012
Seattle Genetics, Inc. (SGEN) Sets Price for Adcetris, Drug May Top $100,000; Investors Dread Dendreon Corporation (DNDN)-Like Rollout     8/24/2011
Seattle Genetics, Inc. (SGEN) and Millennium: The Takeda Oncology Company's Experimental Drug, SGN-35 Shrinks Hodgkin's Tumors, Study Shows     12/7/2010
Medarex, Inc. (MEDX) Announces MDX-060 Receives Orphan Drug Designation For Treatment Of Hodgkin's Disease     10/6/2004
Medarex, Inc. (MEDX) Announces Promising Phase II Results With MDX-060 In Hodgkin's Disease     6/9/2004
Seattle Genetics, Inc. (SGEN) Receives Orphan Drug Designation For SGN-30 In T-Cell Lymphomas     2/26/2004

News from Around the Web
Why So Many Israelis Get Blood Cancer, Hebrew University of Jerusalem Study     8/31/2016
The NIH Spends More On Paperwork Than Researching Hodgkin’s Disease     4/10/2015
Study Finds Gene Links to Common Lymphoma Cancer, Institute of Cancer Research (ICR) Study     11/1/2010
Hodgkin's Treatment, Breast Cancer Linked, University of Florida Study     2/18/2009
University of Southern California Researchers Find New Clues To Risk Of Hodgkin Lymphoma     4/2/2008
Chromosomes Tell Tale of Patient's Risk for New, Future Cancer     4/17/2007
Hodgkin's Disease Therapy Ups Heart Attack Risk     2/7/2007
Cancer Gene Controls Nerve Growth     9/3/2004
Hodgkin's Therapy Tied To Later Heart Problems     8/12/2004
First Woman Pregnant After Ovarian Transplant     6/30/2004
Study: Virus Can Indicate Cancer's Aggressiveness     6/11/2004
Warning Over Cancer Therapy Risk     11/10/2003

Press Releases
NYU Langone Medical Center Release: Combination Immune Therapy Shows Promise Against Hodgkin Lymphoma     12/6/2016
Seattle Genetics (SGEN) Demonstrates Commitment To Improve Hodgkin Lymphoma Treatment Paradigm Through Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations At ISHL 2016     10/20/2016
Kite Pharma (KITE) Details KTE-C19 Launch Preparedness And Near-Term, Next Generation CAR/TCR Product Candidates At Investor Day     10/19/2016
Takeda (TKPYY) Showcases Continued Commitment In Hodgkin Lymphoma During 10th International Symposium On Hodgkin Lymphoma (ISHL)     10/18/2016
Bristol-Myers Squibb (BMY) Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin     10/14/2016
Takeda (TKPYY) Receives European Commission (EC) Approval Of ADCETRIS (Brentuximab Vedotin) For Consolidation Treatment In Post-Transplant Hodgkin Lymphoma     7/6/2016
Seattle Genetics (SGEN) Announces European Commission (EC) Approval Of ADCETRIS (Brentuximab Vedotin) As Consolidation Treatment In Post-Transplant Hodgkin Lymphoma     7/6/2016
Rich Pharma Retains Theradex Systems To Help Advance Its Hodgkin's Lymphoma Indication     6/21/2016
New Data On Bristol-Myers Squibb (BMY)'s Opdivo (Nivolumab) Indicate Benefit In Heavily Pre-Treated Classical Hodgkin Lymphoma Patients In Phase II, Single-Arm Pivotal Trial     6/10/2016
ASCO2016: City of Hope Presents New Cancer Research At American Society Of Clinical Oncology Meeting     6/1/2016
Bristol-Myers Squibb (BMY) Release: Opdivo (nivolumab) Granted First Approval Of A PD-1 Inhibitor In Hematology For The Treatment Of Classical Hodgkin Lymphoma Patients Who Have Relapsed Or Progressed After Auto-HSCT And Post-Transplantation Brentuximab Vedotin By The FDA     5/18/2016
Affimed (AFMD) Presents Data On AFM13-Mediated Innate/Adaptive Immune Crosstalk At The AACR Annual Meeting 2016     4/21/2016
FDA Accepts For Priority Review Bristol-Myers Squibb (BMY)’s Supplemental Biologics License Application For Opdivo (Nivolumab) For The Treatment Of Classical Hodgkin Lymphoma Patients     4/14/2016
European Medicines Agency Validates Bristol-Myers Squibb (BMY)'s Application For Opdivo (Nivolumab) For The Treatment Of Classical Hodgkin Lymphoma Patients     3/31/2016
Affimed Therapeutics AG (AFMD) Enters Into Collaboration With Merck & Co. (MRK) To Evaluate AFM13 In Combination With KEYTRUDA (Pembrolizumab) For Patients With Hodgkin Lymphoma     1/25/2016

//-->